An evaluation into the use of procalcitonin levels as a biomarker of bacterial sepsis to aid the management of intrapartum pyrexia and chorioamnionitis

Sarah Walker; Irasha Harding; Kamran Soomro; Andrew R Bamber; Sophie Carrick; Abdul H Waheed; Rachel E Liebling

doi:10.1016/j.xagr.2022.100064

An evaluation into the use of procalcitonin levels as a biomarker of bacterial sepsis to aid the management of intrapartum pyrexia and chorioamnionitis

AJOG Glob Rep. 2022 Jun 10;2(3):100064. doi: 10.1016/j.xagr.2022.100064. eCollection 2022 Aug.

Authors

Sarah Walker¹, Irasha Harding², Kamran Soomro³, Andrew R Bamber⁴, Sophie Carrick¹, Abdul H Waheed¹, Rachel E Liebling¹

Affiliations

¹ Department of Obstetrics and Gynaecology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom (Dr Walker, Dr Carrick, Dr Waheed, and Dr Liebling).
² UK Health Security Agency, Bristol, United Kingdom (Dr Harding).
³ Department of Computer Science Research Centre, University of the West of England, Bristol, United Kingdom (Dr Soomro).
⁴ Department of Cellular Pathology, North Bristol NHS Trust, Bristol, United Kingdom (Dr Bamber).

Abstract

Background: Procalcitonin is an established biomarker for bacterial sepsis in the nonpregnant population with better diagnostic and prognostic value for bacterial infections.

Objective: This study aimed to evaluate whether procalcitonin levels could be used in the diagnosis and management of intrapartum sepsis in women and their neonates suspected of intrapartum bacterial sepsis.

Study design: A prospective observational cohort study was conducted at the University Hospitals of Bristol and Weston NHS Foundation Trust. Overall, 117 women and their neonates managed for suspected intrapartum sepsis from June 2020 to October 2020 were included. Procalcitonin levels were measured in addition to routine biomarkers white cell count and C-reactive protein in women and their neonates during the initial septic screen and follow-up blood samples. The placentas underwent detailed histopathology. Maternal and neonatal parameters were used to categorize cases into "high-suspicion bacterial sepsis," "equivocal bacterial sepsis," and "low-suspicion bacterial sepsis." The Kruskal-Wallis test was used to compare categories with biomarker values and placental histology scores.

Results: Procalcitonin level was increased in 6 women in the initial septic screen sample, compared with 100 women with an increased C-reactive protein level. There was a significant difference in maternal postnatal procalcitonin results between "high-suspicion bacterial sepsis" and "low-suspicion bacterial sepsis" categories (P=.004). Moreover, 71.2% of placentas showed varying degrees of chorioamnionitis.

Conclusion: In our cohort of women, 94.6% had normal procalcitonin levels while in labor at the time of the septic screen, consistent with the low number of confirmed bacteremia. The result provided a basis that procalcitonin may complement clinical judgment and interpretation of already used prognostic and diagnostic tests, improving patient care in the management of intrapartum sepsis.

Keywords: chorioamnionitis; intrapartum sepsis; procalcitonin; sepsis biomarkers.